On July 15, RemeGen (09995.HK) rose 5.39% in regular trading, reaching HKD 86.75 per share with turnover of HKD 113 million, as the broader biotech sector rallied with multiple peers posting gains of 7-10%.

The rally extends gains driven by the inclusion of RemeGen's flagship drug Telitacicept into the 2026 National Essential Drug List, published on July 9. The updated catalog, the first comprehensive revision in eight years, included Telitacicept as one of only two domestic Class I biological innovative drugs. The new list takes effect September 1 and mandates procurement by public hospitals at all levels, including county-level and primary healthcare institutions, effectively opening grassroots markets previously inaccessible to the company.

Telitacicept, a global-first BLyS/APRIL dual-target fusion protein, has five approved indications domestically. Analysts note the inclusion creates a policy green channel for priority medical insurance negotiation later this year, while the mandatory hospital stocking requirement is expected to significantly expand coverage beyond the current 1,200 tertiary hospitals. Brokerages including Huatai Securities highlighted that the essential drug designation enhances clinical accessibility and prescription priority.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)